Brief: Onconova enrolls first patient in Europe for Phase 3 trial of rigosertib
21/03/2016 11:01
March 21 (Reuters) - Onconova Therapeutics Inc ONTX.O
* Enrolls first patient in Europe for Phase 3 Inspire trial
of rigosertib in higher-risk myelodysplastic syndromes
* Co's collaboration partner in Japan, Korea, Symbio
Pharmaceuticals Ltd, intends to begin enrolling patients in
Japan shortly
Source text for Eikon: ID:nGNXMQEFCa
Further company coverage: ONTX.O
(Bengaluru Newsroom: +1-646-223-8780)